CYP2B6 Polymorphisms in Ketamine

• Status: Completed
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This research study will determine if genetic variation in CYP2B6 affects how the body metabolizes ketamine.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Ketamine

Criteria

Inclusion Criteria:

1. 18-50 yr old

2. CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype (see table) (Note: subjects of other rare genotype but with one or more 516G>T, 785A>G, 983T>C or 1459C>T polymorphism may be enrolled at PI's discretion)

3. Good general health with no remarkable medical conditions

4. BMI <33

5. Provided informed consent

Exclusion Criteria:

1. Known history of liver or kidney disease

2. Use of prescription or non prescription medications, herbals, foods or chemicals known to be metabolized by or affecting CYP2B6

3. Females who are pregnant or nursing

4. Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction)

5. Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential)